Genmab AS

Company Profile

Genmab AS had its IPO on 2009-06-01 under the ticker symbol GMAB.

The company operates in the Healthcare sector and Biotechnology industry. Genmab AS has a staff strength of 2,015 employees.

Stock update

Shares of Genmab AS opened at $36.92 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $36.61 - $37.1, and closed at $36.94.

This is a -1.52% slip from the previous day's closing price.

A total volume of 357,601 shares were traded at the close of the day’s session.

In the last one week, shares of Genmab AS have slipped by -3.75%.

Genmab AS's Key Ratios

Genmab AS has a market cap of $25.35 billion, indicating a price to book ratio of 8.0051 and a price to sales ratio of 2.463.

In the last 12-months Genmab AS’s revenue was $16.37 billion with a gross profit of $14.60 billion and an EBITDA of $6.93 billion. The EBITDA ratio measures Genmab AS's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Genmab AS’s operating margin was 40.13% while its return on assets stood at 13.81% with a return of equity of 17.84%.

In Q2, Genmab AS’s quarterly earnings growth was a negative -28.1% while revenue growth was a positive 32.8%.

Genmab AS’s PE and PEG Ratio

Forward PE

35.3357

Trailing PE

37.6275

PEG

1.2096

Its diluted EPS in the last 12-months stands at $1.02 per share while it has a forward price to earnings multiple of 35.3357 and a PEG multiple of 1.2096. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Genmab AS’s profitability.

Genmab AS stock is trading at a EV to sales ratio of 2.2031 and a EV to EBITDA ratio of 3.5891. Its price to sales ratio in the trailing 12-months stood at 2.463.

Genmab AS stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$31.98 billion

Total Liabilities

$1.99 billion

Operating Cash Flow

$0

Capital Expenditure

$107 million

Dividend Payout Ratio

0%

Genmab AS ended 2024 with $31.98 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $31.98 billion while shareholder equity stood at $28.76 billion.

Genmab AS ended 2024 with $0 in deferred long-term liabilities, $1.99 billion in other current liabilities, 66000000.00 in common stock, $16.17 billion in retained earnings and $0 in goodwill. Its cash balance stood at $10.87 billion and cash and short-term investments were $24.88 billion. The company’s total short-term debt was $82,000,000 while long-term debt stood at $0.

Genmab AS’s total current assets stands at $29.75 billion while long-term investments were $183.00 million and short-term investments were $14.01 billion. Its net receivables were $4.81 billion compared to accounts payable of $0 and inventory worth $51.00 million.

In 2024, Genmab AS's operating cash flow was $0 while its capital expenditure stood at $107 million.

Comparatively, Genmab AS paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$36.94

52-Week High

$47.5

52-Week Low

$31.4

Analyst Target Price

$44.41

Genmab AS stock is currently trading at $36.94 per share. It touched a 52-week high of $47.5 and a 52-week low of $47.5. Analysts tracking the stock have a 12-month average target price of $44.41.

Its 50-day moving average was $38.48 and 200-day moving average was $39.69 The short ratio stood at 5.81 indicating a short percent outstanding of 0%.

Around 1.3% of the company’s stock are held by insiders while 670.1% are held by institutions.